Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

Recruiting now

Conditions studied: Non Small Cell Lung Carcinoma NSCLC

In brief

Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity. This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.

Key facts

Study ID

NCT07369596

Run by

University of Malaya

People needed

150

Starts

2026-01-01

Expected to finish

2026-12-31

Last updated by the study team

2026-06-02

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥65 years
• Histologically confirmed stage IV NSCLC
• Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
• Treated with at least ONE cycle of first-line chemotherapy

You may not qualify if…

• Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting
• Incomplete survival data

Where it is running

• Queen Mary Hospital, The University of Hong Kong — Hong Kong, Hong Kong (enrolling)
• Hospital Tengku Ampuan Afzan — Kuantan, Pahang, Malaysia (enrolling)
• Hospital Wanita dan Kanak-Kanak Sabah — Kota Kinabalu, Sabah, Malaysia (enrolling)
• Universiti Malaya Medical Centre — Kuala Lumpur, Malaysia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.